{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:42:44Z","timestamp":1793781764134,"version":"4.6.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T00:00:00Z","timestamp":1660867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T00:00:00Z","timestamp":1660867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100011404","name":"Indivior","doi-asserted-by":"publisher","award":["EXPOUK"],"award-info":[{"award-number":["EXPOUK"]}],"id":[{"id":"10.13039\/100011404","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Sublingual tablet buprenorphine (BUP-SL) and oral liquid methadone (MET) are the daily, standard-of-care (SOC) opioid agonist treatment medications for opioid use disorder (OUD). A sizable proportion of the OUD treatment population is not exposed to sufficient treatment to attain the desired clinical benefit. Two promising therapeutic technologies address this deficit: long-acting injectable buprenorphine and personalised psychosocial interventions (PSI). This study will determine (A) the effectiveness and cost-effectiveness \u2014 monthly injectable, extended-release (BUP-XR) in a head-to-head comparison with BUP-SL and MET, and (B) the effectiveness of BUP-XR with adjunctive PSI versus BUP-SL and MET with PSI. Safety, retention, craving, substance use, quality-adjusted life years, social functioning, and subjective recovery from OUD will be also evaluated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a pragmatic, multi-centre, open-label, parallel-group, superiority RCT, with a qualitative (mixed-methods) evaluation. The study population is adults. The setting is five National Health Service community treatment centres in England and Scotland. At each centre, participants will be randomly allocated (1:1) to BUP-XR or SOC. At the London study co-ordinating centre, there will also be allocation of participants to BUP-XR with PSI or SOC with PSI. With 24 weeks of study treatment, the primary outcome is days of abstinence from non-medical opioids during study weeks 2\u201324 combined with up to 12 urine drug screen tests for opioids. For 90% power (alpha, 5%; 15% inflation for attrition), 304 participants are needed for the BUP-XR versus SOC comparison. With the same planning parameters, 300 participants are needed for the BUP-XR and PSI versus SOC and PSI comparison. Statistical and health economic analysis plans will be published before data-lock on the Open Science Framework. Findings will be reported in accordance with the Consolidated Standards of Reporting Trials and Consolidated Health Economic Evaluation Reporting Standards.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This pragmatic randomised controlled trial is the first evaluation of injectable BUP-XR versus the SOC medications BUP-SL and MET, with personalised PSI. If there is evidence for the superiority of BUP-XR over SOC medication, study findings will have substantial implications for OUD clinical practice and treatment policy in the UK and elsewhere.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>EU Clinical Trials register 2018-004460-63.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-022-06595-0","type":"journal-article","created":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T11:04:34Z","timestamp":1660907074000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1307-2498","authenticated-orcid":false,"given":"John","family":"Marsden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Kelleher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zo\u00eb","family":"Hoare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dyfrig","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jatinder","family":"Bisla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Cape","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Cowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Dewhurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Hearn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Lowry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"McCusker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey","family":"Myton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Quarshie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Vanderwaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April","family":"Wareham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eilish","family":"Gilvarry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Mitcheson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,19]]},"reference":[{"key":"6595_CR1","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed: American Psychiatric Association: American Psychiatric Publishing; 2013. DSM5","DOI":"10.1176\/appi.books.9780890425596"},{"key":"6595_CR2","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1111\/add.14234","volume":"113","author":"A Peacock","year":"2018","unstructured":"Peacock A, Leung J, Larney S, Colledge S, Hickman M, Rehm J, et al. Global statistics on alcohol, tobacco, and illicit drug use: 2017 status report. Addiction. 2018;113:1905\u201326.","journal-title":"Addiction."},{"key":"6595_CR3","doi-asserted-by":"publisher","unstructured":"Birnbaum HG, White AG, Schiller M, Waldman T, Cleveland JM, Roland CL. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med. 2011;12(4):657\u201367. https:\/\/doi.org\/10.1111\/j.1526-4637.2011.01075.x. Epub 2011 Mar 10.","DOI":"10.1111\/j.1526-4637.2011.01075.x"},{"issue":"1","key":"6595_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-019-0137-5","volume":"6","author":"J Strang","year":"2020","unstructured":"Strang J, Volkow ND, Degenhardt L, Hickman M, Johnson K, Koob GF, et al. Opioid use disorder. Nat Rev Dis Primers. 2020;6(1):3.","journal-title":"Nat Rev Dis Primers"},{"key":"6595_CR5","unstructured":"Office for National Statistics. Deaths related to drug poisoning in England and Wales: 2020 registrations. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/deaths\/bulletins\/deathsrelatedtodrugpoisoninginenglandandwales\/2020. (Accessed on 26 Oct 2021)."},{"key":"6595_CR6","unstructured":"National Records of Scotland. Drug related deaths in Scotland in 2020. https:\/\/www.nrscotland.gov.uk\/files\/statistics\/drug-related-deaths\/20\/drug-related-deaths-20-pub.pdf. (Accessed on 26 Oct 21)."},{"key":"6595_CR7","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1111\/j.1360-0443.2012.03971.x","volume":"107","author":"J Marsden","year":"2012","unstructured":"Marsden J, Eastwood B, Jones H, Bradbury C, Hickman M, Knight J, et al. Risk adjustment of heroin treatment outcomes for comparative performance assessment in England. Addiction. 2012;107:2161\u201372.","journal-title":"Addiction."},{"key":"6595_CR8","first-page":"791","volume":"34","author":"KM Broome","year":"1999","unstructured":"Broome KM, Flynn PM, Simpson DD. Psychiatric comorbidity measures as predictors of retention in drug abuse treatment programs. Health Serv Res. 1999;34:791\u2013806.","journal-title":"Health Serv Res"},{"key":"6595_CR9","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1037\/a0015252","volume":"77","author":"MD Litt","year":"2009","unstructured":"Litt MD, Kadden RM, Kabela-Cormier E, Petry NM. Changing network support for drinking: network support project 2-year follow-up. J Consult Clin Psychol. 2009;77:229\u201342.","journal-title":"J Consult Clin Psychol"},{"key":"6595_CR10","doi-asserted-by":"crossref","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009:CD002209.","DOI":"10.1002\/14651858.CD002209.pub2"},{"key":"6595_CR11","doi-asserted-by":"crossref","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014:CD002207.","DOI":"10.1002\/14651858.CD002207.pub4"},{"issue":"SUPPL. 1","key":"6595_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.drugpo.2005.02.008","volume":"16","author":"M Farrell","year":"2005","unstructured":"Farrell M, Gowing L, Marsden J, Ling W, Ali R. Effectiveness of drug dependence treatment in HIV prevention. Int J Drug Policy. 2005;16(SUPPL. 1):67\u201375.","journal-title":"Int J Drug Policy"},{"key":"6595_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0740-5472(99)00097-5","volume":"19","author":"M Gossop","year":"2000","unstructured":"Gossop M, Marsden J, Stewart D, Rolfe A. Patterns of drinking and drinking outcomes among drug misusers. 1-year follow-up results. J Subst Abuse Treat. 2000;19:45\u201350.","journal-title":"J Subst Abuse Treat"},{"key":"6595_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0740-5472(01)00206-9","volume":"22","author":"D Stewart","year":"2002","unstructured":"Stewart D, Gossop M, Marsden J. Reductions in non-fatal overdose after drug misuse treatment: results from the National Treatment Outcome Research Study (NTORS). J Subst Abuse Treat. 2002;22:1\u20139.","journal-title":"J Subst Abuse Treat"},{"key":"6595_CR15","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1111\/add.12971","volume":"110","author":"M White","year":"2015","unstructured":"White M, Burton R, Darke S, Eastwood B, Knight J, Millar T, et al. Fatal opioid poisoning: a counterfactual model to estimate the preventive effect of treatment for opioid use disorder in England. Addiction. 2015;110:1321\u20139.","journal-title":"Addiction."},{"key":"6595_CR16","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/add.13193","volume":"111","author":"M Pierce","year":"2016","unstructured":"Pierce M, Bird SM, Hickman M, Marsden J, Dunn G, Jones A, et al. Impact of treatment for opioid dependence on fatal drug-related poisoning: a national cohort study in England. Addiction. 2016;111:298\u2013308.","journal-title":"Addiction."},{"key":"6595_CR17","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1111\/add.13779","volume":"112","author":"J Marsden","year":"2017","unstructured":"Marsden J, Stillwell G, Jones H, Cooper A, Eastwood B, Farrell M, et al. Does exposure to opioid substitution treatment in prison reduce the risk of death after release? A national prospective observational study in England. Addiction. 2017;112:1408\u201318.","journal-title":"Addiction"},{"key":"6595_CR18","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1111\/add.12971","volume":"110","author":"M White","year":"2015","unstructured":"White M, Burton R, Darke S, Eastwood B, Knight J, Millar T, et al. Fatal opioid poisoning: a counterfactual model to estimate the preventive effect of treatment for opioid use disorder in England. Addiction. 2015;110:1321\u20139.","journal-title":"Addiction"},{"key":"6595_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e5945","volume":"345","author":"GJ MacArthur","year":"2012","unstructured":"MacArthur GJ, Minozzi S, Martin N, Vickerman P, Deren S, Bruneau J, et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ. 2012;345:e5945.","journal-title":"BMJ"},{"key":"6595_CR20","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/add.14059","volume":"113","author":"A Russolillo","year":"2018","unstructured":"Russolillo A, Moniruzzaman A, McCandless LC, Patterson M, Somers JM. Associations between methadone maintenance treatment and crime: a 17-year longitudinal cohort study of Canadian provincial offenders. Addiction. 2018;113:656\u201367.","journal-title":"Addiction"},{"key":"6595_CR21","doi-asserted-by":"crossref","unstructured":"Nielsen S, Larance B, Degenhardt L, Gowing L, Kehler C, Lintzeris N. Opioid agonist treatment for pharmaceutical opioid dependent people: The Cochrane Library; 2016.","DOI":"10.1002\/14651858.CD011117.pub2"},{"key":"6595_CR22","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0740-5472(98)00037-3","volume":"16","author":"YI Hser","year":"1999","unstructured":"Hser YI, Polinsky ML, Maglione M, Anglin MD. Matching clients\u2019 needs with drug treatment services. J Subst Abuse Treat. 1999;16:299\u2013305.","journal-title":"J Subst Abuse Treat"},{"key":"6595_CR23","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1046\/j.1360-0443.2003.00296.x","volume":"98","author":"M Gossop","year":"2003","unstructured":"Gossop M, Marsden J, Stewart D, Kidd T. The National Treatment Outcome Research Study (NTORS): 4-5 year follow-up results. Addiction. 2003;98:291\u2013303.","journal-title":"Addiction."},{"key":"6595_CR24","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/S0140-6736(09)61420-3","volume":"374","author":"J Marsden","year":"2008","unstructured":"Marsden J, Eastwood B, Bradbury C, Dale-Perera A, Farrell M, Hammond P, et al. Effectiveness of community treatments for heroin and crack cocaine addiction in England: a prospective, in-treatment cohort study. Lancet. 2008;374:1262\u201370.","journal-title":"Lancet"},{"key":"6595_CR25","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.drugalcdep.2017.03.013","volume":"176","author":"B Eastwood","year":"2017","unstructured":"Eastwood B, Strang J, Marsden J. Effectiveness of treatment for opioid use disorder: a national, five-year, prospective, observational study in England. Drug Alcohol Depend. 2017;176:139\u201347.","journal-title":"Drug Alcohol Depend"},{"key":"6595_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232086","volume":"15","author":"A O\u2019Connor","year":"2020","unstructured":"O\u2019Connor A, Cousins G, Durand L, Barry J, Boland F. Retention of patients in opioid substitution treatment: a systematic review. PLoS One. 2020;15:e0232086.","journal-title":"PLoS One"},{"key":"6595_CR27","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.pnpbp.2010.12.002","volume":"35","author":"G Gerra","year":"2011","unstructured":"Gerra G, Saenz E, Busse A, Maremmani I, Ciccocioppo R, Zaimovic A, et al. Supervised daily consumption, contingent take-home incentive and non-contingent take-home in methadone maintenance. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:483\u20139.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"6595_CR28","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.drugalcdep.2018.03.052","volume":"188","author":"B Eastwood","year":"2018","unstructured":"Eastwood B, Strang J, Marsden J. Continuous opioid substitution treatment over five years: heroin use trajectories and outcomes. Drug Alcohol Depend. 2018;188:200\u20138.","journal-title":"Drug Alcohol Depend"},{"key":"6595_CR29","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/JCP.0000000000000434","volume":"36","author":"AF Nasser","year":"2016","unstructured":"Nasser AF, Greenwald MK, Heidbreder C. Sustained-release buprenorphine (RBP-6000) blocks the effects of opioid challenge with hydromorphone in subjects with opioid use disorder. J Clin Psychopharmacol. 2016;36:18\u201326.","journal-title":"J Clin Psychopharmacol"},{"key":"6595_CR30","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/S0140-6736(18)32259-1","volume":"1073","author":"BR Haight","year":"2019","unstructured":"Haight BR, Learned SM, Laffont CM, Fudala PJ, Zhao Y, Garofalo AS, et al. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2019;1073:778\u201390.","journal-title":"Lancet"},{"key":"6595_CR31","doi-asserted-by":"crossref","unstructured":"Amato L, Minozzi S, Davoli M, Vecchi S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev. 2011:CD004147.","DOI":"10.1002\/14651858.CD004147.pub4"},{"key":"6595_CR32","first-page":"310","volume":"21","author":"J Neale","year":"2014","unstructured":"Neale J, Finch E, Marsden J, Mitcheson L, Rose D, Strang J, et al. How should we measure addiction recovery? Analysis of service provider perspectives using online Delphi groups. Drugs: Educ, Prev Policy. 2014;21:310\u201323.","journal-title":"Drugs: Educ, Prev Policy"},{"key":"6595_CR33","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cct.2016.12.003","volume":"53","author":"J Marsden","year":"2017","unstructured":"Marsden J, Stillwell G, Hellier J, Marsden J, Stillwell G, Hellier J, et al. Effectiveness of adjunctive, personalised psychosocial intervention for non-response to opioid agonist treatment: study protocol for a pragmatic randomised controlled trial. Contemp Clin Trials. 2017;53:36\u201343.","journal-title":"Contemp Clin Trials"},{"key":"6595_CR34","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S2215-0366(19)30097-5","volume":"6","author":"J Marsden","year":"2019","unstructured":"Marsden J, Stillwell G, James K, Shearer J, Byford S, Hellier J, et al. Efficacy, and cost-effectiveness of an adjunctive personalised psychosocial intervention in treatment-resistant maintenance opioid agonist therapy: a pragmatic, open-label, randomised controlled trial. Lancet Psychiatry. 2019;6:391\u2013402.","journal-title":"Lancet Psychiatry"},{"key":"6595_CR35","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. Declaration of Helsinki ethical principles for medical research involving human subjects. JAMA. 2013;310:2191\u20134.","journal-title":"JAMA."},{"key":"6595_CR36","unstructured":"Medical Research Council Guidelines for Good Clinical Practice. https:\/\/www.ukri.org\/councils\/mrc\/guidance-for-applicants\/policies-and-guidance-for-researchers\/supporting-good-research-practice\/ (Accessed 21 Oct 2021)."},{"key":"6595_CR37","volume-title":"Research governance framework for health and social care","author":"Department of Health","year":"2005","unstructured":"Department of Health. Research governance framework for health and social care. 2nd ed; 2005. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/139565\/dh_4122427.pdf. (Accessed 21 Oct 2021)","edition":"2"},{"key":"6595_CR38","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0140-6736(12)62160-6","volume":"381","author":"A-W Chan","year":"2013","unstructured":"Chan A-W, Tetzlaff J, Altman D, Dickersin K, Moher D. SPIRIT: new guidance for content of clinical trial protocols. Lancet. 2013;381:91\u20132.","journal-title":"Lancet."},{"key":"6595_CR39","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ebiom.2018.01.039","volume":"29","author":"J Marsden","year":"2018","unstructured":"Marsden J, Goetz C, Meynen T, Mitcheson L, Stillwell G, Eastwood B, et al. Memory-focused cognitive therapy for cocaine use disorder: theory, procedures and preliminary evidence from an external pilot randomised controlled trial. EBioMedicine. 2018;29:177\u201389.","journal-title":"EBioMedicine."},{"key":"6595_CR40","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.conctc.2017.10.009","volume":"8","author":"J Marsden","year":"2017","unstructured":"Marsden J, Goetz C, Meynen T, Mitcheson L, Stillwell G, Eastwood J. Memory-focused cognitive therapy for cocaine use disorder: rationale, design and protocol for an external pilot randomised controlled trial. Contemp Clin Trials Commun. 2017;8:264\u201373.","journal-title":"Contemp Clin Trials Commun"},{"key":"6595_CR41","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1111\/add.15405","volume":"116","author":"N Lowry","year":"2021","unstructured":"Lowry N, Marsden J, Clydesdale B, Eastwood B, Havelka EM, Goetz C. Acute impact of self-guided mental imagery on craving in cocaine use disorder: a mixed-methods analysis of a randomized controlled trial. Addiction. 2021;116:2418\u201330.","journal-title":"Addiction."},{"key":"6595_CR42","unstructured":"Miller WR, Rollnick S. Motivational interviewing: helping people change (applications of motivational interviewing): The Guilford Press; 2012."},{"key":"6595_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/9780470661420","volume-title":"Applied cognitive and behavioural approaches to the treatment of addiction: a practical treatment guide","author":"L Mitcheson","year":"2010","unstructured":"Mitcheson L, Maslin J, Meynen T, Morrison T, Hill R, Wanigaratne S. Applied cognitive and behavioural approaches to the treatment of addiction: a practical treatment guide. Chichester: Wiley-Blackwell; 2010."},{"key":"6595_CR44","unstructured":"Higgins ST, Silverman SH, Heil SH. Contingency management in substance abuse treatment. New York: Guilford Press; 2007. p. 380. ISBN: 978-1-59385-571-0."},{"key":"6595_CR45","volume-title":"Overcoming depression. A self-help guide using cognitive behavioural techniques","author":"P Gilbert","year":"2009","unstructured":"Gilbert P. Overcoming depression. A self-help guide using cognitive behavioural techniques. London: Robinson; 2009."},{"key":"6595_CR46","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1151\/spp042230","volume":"2","author":"W Fals-Stewart","year":"2004","unstructured":"Fals-Stewart W, O\u2019Farrell TJ, Birchler GR. Behavioral couples therapy for substance abuse: rationale, methods, and findings. Sci Pract Perspect. 2004;2:30\u201341.","journal-title":"Sci Pract Perspect"},{"key":"6595_CR47","unstructured":"Nowinski J, Baker S, Carroll K. Twelve step facilitation therapy manual. A clinical research guide for therapists treating individuals with alcohol abuse and dependence. National Institute on Alcohol Abuse and Alcoholism Project MATCH Monograph Series Volume 1: National Institute on Alcohol Abuse and Alcoholism; 1999."},{"key":"6595_CR48","unstructured":"University College London scale for rating core and generic therapeutic skills. https:\/\/www.ucl.ac.uk\/pals\/ucl-centre-outcomes-research-and-effectiveness. (Accessed: 21 Oct 21)."},{"key":"6595_CR49","first-page":"1","volume":"2358","author":"TC Hoffmann","year":"2014","unstructured":"Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;2358:1\u201312.","journal-title":"BMJ."},{"key":"6595_CR50","unstructured":"First MB, Williams JBW, Karg R, Spitzer RL. Structured Clinical Interview for DSM-5 Disorders \u2013 clinician version (SCID-5-CV): American Psychiatric Association; 2015."},{"key":"6595_CR51","volume-title":"Timeline Follow-back: a calendar method for assessing alcohol and drug use. User\u2019s guide, Addiction Research Foundation, Toronto, Ontario","author":"LC Sobell","year":"1996","unstructured":"Sobell LC, Sobell MC. Timeline Follow-back: a calendar method for assessing alcohol and drug use. User\u2019s guide, Addiction Research Foundation, Toronto, Ontario; 1996."},{"key":"6595_CR52","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1111\/j.1360-0443.2008.02284.x","volume":"103","author":"J Marsden","year":"2008","unstructured":"Marsden J, Farrell M, Bradbury C, Dale-Perera A, Eastwood B, Roxburgh M, et al. Development of the treatment outcomes profile. Addiction. 2008;103:1450\u201360.","journal-title":"Addiction"},{"key":"6595_CR53","first-page":"47","volume":"247","author":"WK Bickel","year":"1988","unstructured":"Bickel WK, Stitzer ML, Bigelow IA, Jasinski JR, Johnson RE. Dose-related blockade of opioid challenge effects in opioid dependent humans. J Pharmacol Exp Ther. 1988;247:47\u201353.","journal-title":"J Pharmacol Exp Ther"},{"key":"6595_CR54","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/0376-8716(96)01218-5","volume":"40","author":"DE McMillan","year":"1996","unstructured":"McMillan DE, Gilmore-Thomas K. Stability of opioid craving over time as measured by visual analog scales. Drug Alcohol Depend. 1996;40:235\u20139.","journal-title":"Drug Alcohol Depend"},{"key":"6595_CR55","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1111\/add.12472","volume":"109","author":"J May","year":"2014","unstructured":"May J, Andrade J, Kavanagh DJ, Feeney GFX, Gullo MJ, Statham DJ, et al. The Craving Experience Questionnaire: a brief, theory-based measure of consummatory desire and craving. Addiction. 2014;109:728\u201335.","journal-title":"Addiction"},{"key":"6595_CR56","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.addbeh.2014.09.016","volume":"36","author":"J May","year":"2015","unstructured":"May J, Andrade J, Kavanagh DJ. The elaborated intrusion theory of desire: a 10-year retrospective and implications for addiction treatments. Addict Behav. 2015;36:29\u201334.","journal-title":"Addict Behav"},{"key":"6595_CR57","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine ZS, Phillips NA, B\u00e9dirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment (MoCA): a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695\u20139.","journal-title":"J Am Geriatr Soc"},{"key":"6595_CR58","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0006-3223(02)01866-8","volume":"54","author":"AJ Rush","year":"2003","unstructured":"Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, et al. The 16-item Quick Inventory of Depressive Symptomatology (QIDS) Clinician Rating (QIDS-C) and Self-Report (QIDS-SR): a psychoMETric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54:573\u201383.","journal-title":"Biol Psychiatry"},{"key":"6595_CR59","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s10862-015-9529-3","volume":"38","author":"EA Kaufman","year":"2016","unstructured":"Kaufman EA, Xia M, Fosco G, Yaptangco M, Skidmore CR, Crowell S. The Difficulties in Emotion Regulation Scale Short Form (DERS-SF): validation and replication in adolescent and adult samples. J Psychopathol Behav Assess. 2016;38:443\u20135.","journal-title":"J Psychopathol Behav Assess"},{"key":"6595_CR60","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1192\/bjp.180.5.461","volume":"180","author":"JC Mundt","year":"2002","unstructured":"Mundt JC, Marks IM, Shear MK, Greist JM. The Work and Social Adjustment Scale: a simple measure of impairment in functioning. Br J Psychiatry. 2002;180:461\u20134.","journal-title":"Br J Psychiatry"},{"key":"6595_CR61","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1097\/00006842-200203000-00008","volume":"64","author":"K Kroenke","year":"2002","unstructured":"Kroenke K, Spitzer RL, Williams JB. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med. 2002;64:258\u201366.","journal-title":"Psychosom Med"},{"key":"6595_CR62","first-page":"613","volume":"50","author":"K Kroenke","year":"2009","unstructured":"Kroenke K, Spitzer RL, Williams JBW, L\u00f6we B. An ultra-brief screening scale for anxiety and depression: the PHQ-4. Psychosomatics. 2009;50:613\u201321.","journal-title":"Psychosomatics."},{"key":"6595_CR63","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","volume":"37","author":"R Brooks","year":"1996","unstructured":"Brooks R. EuroQol: the current state of play. Health Policy. 1996;37:53\u201372.","journal-title":"Health Policy"},{"key":"6595_CR64","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000484239","volume":"23","author":"L Strada","year":"2017","unstructured":"Strada L, Franke GH, Schulte B, Reimer J, Verthein U. Development of OSTQOL: a measure of quality of life for patients in opioid substitution treatment. Eur Addict Res. 2017;23:238\u201348.","journal-title":"Eur Addict Res"},{"key":"6595_CR65","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1192\/bjp.bp.112.111583","volume":"203","author":"S Byford","year":"2013","unstructured":"Byford S, Barrett B, Metrebian N, Groshkova T, Cary N, Lintzeris N, et al. Cost-effectiveness of injectable opioid treatment v. oral, methadone for chronic heroin addiction. Br J Psychiatry. 2013;203:341\u20139.","journal-title":"Br J Psychiatry"},{"key":"6595_CR66","volume-title":"ECDU assessment manual for psychopharmacology. Revised","author":"W Guy","year":"1976","unstructured":"Guy W. ECDU assessment manual for psychopharmacology. Revised. Maryland: National Institute of Mental Health; 1976."},{"key":"6595_CR67","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.drugalcdep.2016.06.006","volume":"165","author":"J Neale","year":"2016","unstructured":"Neale J, Vitoratou S, Finch E, Lennon P, Mitcheson L, Panebianco D, et al. Development and validation of \u2018SURE\u2019: a patient reported outcome measure (PROM) for recovery from drug and alcohol dependence. Drug Alcohol Depend. 2016;165:159\u201367.","journal-title":"Drug Alcohol Depend"},{"key":"6595_CR68","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.drugalcdep.2014.03.018","volume":"139","author":"J Marsden","year":"2014","unstructured":"Marsden J, Eastwood B, Ali R, Burkinshaw P, Chohan G, Copello A, et al. Development of the Addiction Dimensions for Assessment and Personalised Treatment (ADAPT). Drug Alcohol Depend. 2014;139:121\u201331.","journal-title":"Drug Alcohol Depend"},{"key":"6595_CR69","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1186\/s13063-018-2884-0","volume":"19","author":"JA Cook","year":"2018","unstructured":"Cook JA, Julious SA, Sones W, Hampson LV, Hewitt C, Berlin JA, et al. DELTA2 guidance on choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial. Trials. 2018;19:606.","journal-title":"Trials."},{"key":"6595_CR70","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1745-6215-11-32","volume":"11","author":"KF Schulz","year":"2010","unstructured":"Schulz KF, Altman DG, Moher D. CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Trials. 2010;11:32.","journal-title":"Trials"},{"key":"6595_CR71","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jval.2020.10.002","volume":"24","author":"JC Thorn","year":"2021","unstructured":"Thorn JC, Davies CF, Brookes ST, Noble SM, Dritsaki M, Gray E, et al. Content of Health Economics Analysis Plans (HEAPs) for trial-based economic evaluations: expert Delphi consensus survey. Value Health. 2021;24:539\u201347.","journal-title":"Value Health"},{"key":"6595_CR72","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s40273-013-0032-y","volume":"31","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Pharmacoeconomics. 2013;31:361\u20137.","journal-title":"Pharmacoeconomics"},{"key":"6595_CR73","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/hec.944","volume":"14","author":"A Manca","year":"2005","unstructured":"Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ. 2005;14:487\u201396.","journal-title":"Health Econ"},{"key":"6595_CR74","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/hec.635","volume":"10","author":"E Fenwick","year":"2001","unstructured":"Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. 2001;10:779\u201387.","journal-title":"Health Econ"},{"key":"6595_CR75","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1146\/annurev.med.59.062606.122232","volume":"59","author":"PW Lavori","year":"2008","unstructured":"Lavori PW, Dawson R. Adaptive treatment strategies in chronic disease. Annu Rev Med. 2008;59:443\u201353.","journal-title":"Annu Rev Med"},{"key":"6595_CR76","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1111\/add.14546","volume":"114","author":"J Marsden","year":"2019","unstructured":"Marsden J, Tai B, Ali R, Hu L, Rush AJ, Volkow N. Measurement-based care using DSM-5 for opioid use disorder: can we make opioid medication treatment more effective? Addiction. 2019;114:1346\u201311353.","journal-title":"Addiction."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06595-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-06595-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06595-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T12:14:54Z","timestamp":1660911294000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-06595-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,19]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["6595"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-06595-0","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,19]]},"assertion":[{"value":"29 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.K., J.M., and L.M. declare an unrestricted research grant at IoPPN and SLaM from Indivior via Action on Addiction for a randomised controlled trial of personalised PSI among treatment-resistant patients enrolled in OUD SOC (published in 2019).J.M. declares research grants from the National Institute for Health Research (NIHR; randomised controlled trial of depot naltrexone for OUD, and a randomised controlled trial of acamprosate for AUD) and the NIHR Biomedical Research Centre for Mental Health at South London and Maudsley NHS Mental Health Foundation Trust (SLaM; randomised controlled trial of novel cognitive therapy for cocaine use disorder). J.M. is a clinical academic consultant for the US National Institute on Drug Abuse, Centre for Clinical Trials Network, and he was Senior Academic Advisor for the Alcohol, Drug, Tobacco, Justice Division, Health Improvement, Public Health England (to September 2021). He received honoraria and travel support from Reckitt-Benckiser (2016; treatment of OUD) and from PCM Scientific and Martindale for the Improving Outcomes in Treatment of Opioid Dependence conference (2018 and 2021).F.C. declares co-applicant status for the Tenovus Scotland Research Grant for examining the impact of the UK Government\u2019s reclassification of gabapentinoids.The other authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"697"}}